Literature DB >> 32531218

Vaginal delivery in COVID-19 pregnant women: anorectum as a potential alternative route of SARS-CoV-2 transmission.

Andrea Roberto Carosso1, Stefano Cosma2, Chiara Benedetto2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32531218      PMCID: PMC7283067          DOI: 10.1016/j.ajog.2020.06.012

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


× No keyword cloud information.
To the Editors: In a recently published article in the Journal, Cui et al reported that they did not find severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the genital tract of 35 patients of reproductive and postmenopausal age who received a diagnosis of coronavirus disease 2019 (COVID-19). All vaginal and cervical swabs were reportedly negative for SARS-CoV-2, whereas 1 anal swab sample tested positive. The authors concluded from these findings that the lower female genital tract may not be a transmission route for SARS-CoV-2 and that such evidence may guide the choice of delivery method in women with COVID-19. Although the authors are to be commended, their conclusions warrant careful consideration. In a recent report, we described the first case of potential vertical transmission during vaginal delivery in a woman with rectal and stool swabs positive for SARS-CoV-2. This transmission route has been underestimated, however, probably because of the high incidence of cesarean deliveries in pregnant women with COVID-19. Cases of infants with a positive test result for SARS-CoV-2 after vaginal birth have come to light without a clear explanation of the transmission route and with no anal swabs taken. SARS-CoV-2 has been detected in the stools of 1 of 3 nonpregnant patients with COVID-19, but its prevalence in the anal swab of pregnant patients is still unknown. The low prevalence reported by Cui et al (1/35 [2.8%]) stems likely from several factors: small sample size, not all patients having a positive oropharyngeal swab, and time between onset of symptoms and sample collection (8–41 days). Furthermore, the article does not mention whether the patients had diarrhea or other intestinal symptoms or whether stool tests for SARS-CoV-2 were performed. These limitations might have underestimated the number of anal swabs positive for SARS-CoV-2. In the current state, obstetricians should maintain their obstetrical indications because contamination does not mean infection. Indeed, preventive measures during vaginal delivery, reduced viral load exposure, and potential transplacental passage of antibodies from the mother to the fetus could reduce the risk of neonatal infection. To shed further light on this topic, mothers whose newborns test positive for SARS-CoV-2 after vaginal birth should be tested using anal swab to establish the true incidence of this transmission route in large samples and to avert the risk of underestimating it.
  11 in total

1.  Healthy Aging in the Time of Corona Pandemic.

Authors:  Asim Kurjak; Miro Jakovljevic; Izet Masic; Milan Stanojevic
Journal:  Med Arch       Date:  2021-02

2.  No infectious SARS-CoV-2 in breast milk from a cohort of 110 lactating women.

Authors:  Paul Krogstad; Deisy Contreras; Hwee Ng; Nicole Tobin; Christina D Chambers; Kerri Bertrand; Lars Bode; Grace M Aldrovandi
Journal:  Pediatr Res       Date:  2022-01-19       Impact factor: 3.953

Review 3.  A critical review on SARS-CoV-2 infectivity in water and wastewater. What do we know?

Authors:  Alexandre Giacobbo; Marco Antônio Siqueira Rodrigues; Jane Zoppas Ferreira; Andréa Moura Bernardes; Maria Norberta de Pinho
Journal:  Sci Total Environ       Date:  2021-02-09       Impact factor: 7.963

4.  Prenatal Biochemical and Ultrasound Markers in COVID-19 Pregnant Patients: A Prospective Case-Control Study.

Authors:  Stefano Cosma; Andrea Roberto Carosso; Fulvio Borella; Jessica Cusato; Marialuisa Bovetti; Federica Bevilacqua; Marco Carosso; Fiammetta Gervasoni; Andrea Sciarrone; Luca Marozio; Alberto Revelli; Alessandro Rolfo; Claudia Filippini; Valeria Ghisetti; Giovanni Di Perri; Chiara Benedetto
Journal:  Diagnostics (Basel)       Date:  2021-02-26

5.  No Evidence of Infectious SARS-CoV-2 in Human Milk: Analysis of a Cohort of 110 Lactating Women.

Authors:  Paul Krogstad; Deisy Contreras; Hwee Ng; Nicole Tobin; Christina D Chambers; Kerri Bertrand; Lars Bode; Grace Aldrovandi
Journal:  medRxiv       Date:  2021-04-07

Review 6.  Is There a Role for SARS-CoV-2/COVID-19 on the Female Reproductive System?

Authors:  Silvia D'Ippolito; Francesca Turchiano; Amerigo Vitagliano; Gennaro Scutiero; Antonio Lanzone; Giovanni Scambia; Pantaleo Greco
Journal:  Front Physiol       Date:  2022-03-02       Impact factor: 4.566

7.  Obstetric and neonatal outcomes after SARS-CoV-2 infection in the first trimester of pregnancy: A prospective comparative study.

Authors:  Stefano Cosma; Andrea Roberto Carosso; Jessica Cusato; Fulvio Borella; Luca Bertero; Marialuisa Bovetti; Federica Bevilacqua; Giulio Mengozzi; Raffaela Mazzone; Valeria Ghisetti; Giovanni Di Perri; Chiara Benedetto
Journal:  J Obstet Gynaecol Res       Date:  2021-11-23       Impact factor: 1.697

8.  The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy.

Authors:  Stefano Cosma; Fulvio Borella; Andrea Carosso; Andrea Sciarrone; Jessica Cusato; Silvia Corcione; Giulio Mengozzi; Mario Preti; Dionyssios Katsaros; Giovanni Di Perri; Chiara Benedetto
Journal:  J Med Virol       Date:  2020-08-13       Impact factor: 20.693

9.  Why Not Lose Faith in Science in the Fight Against Coronavirus.

Authors:  Asim Kurjak; Olus Api; Izet Masic
Journal:  Mater Sociomed       Date:  2020-12

10.  Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts.

Authors:  Luca Bertero; Fulvio Borella; Paola Cassoni; Chiara Benedetto; Giovanni Botta; Andrea Carosso; Stefano Cosma; Marialuisa Bovetti; Marco Carosso; Giancarlo Abbona; Giammarco Collemi; Mauro Papotti
Journal:  Virchows Arch       Date:  2021-05-01       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.